Sandoz Biosimilar Closer To Launch After Court Finds ‘Patent Dance’ Isn’t Mandatory
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz would not say when it plans to launch Zarxio (filgrastim-sndz), but has said it would give Amgen five days notice.